Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chie Shimamoto is active.

Publication


Featured researches published by Chie Shimamoto.


Journal of Biological Chemistry | 2006

Cyclic Phosphatidic Acid Is Produced by Autotaxin in Blood

Satomi Tsuda; Shinichi Okudaira; Keiko Moriya-Ito; Chie Shimamoto; M. Tanaka; Junken Aoki; Hiroyuki Arai; Kimiko Murakami-Murofushi; Tetsuyuki Kobayashi

Cyclic phosphatidic acid (cPA), an analog of lysophosphatidic acid (LPA), was previously identified in human serum. Although cPA possesses distinct physiological activities not elicited by LPA, its biochemical origins have scarcely been studied. In the present study, we assayed cPA formation from lysophosphatidylcholine in fetal bovine serum and found significant activity of transphosphatidylation that generated cPA. The cPA-producing enzyme was purified from fetal bovine serum using five chromatographic steps yielding a 100-kDa protein with cPA biosynthetic activity. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of its tryptic peptides revealed that the enzyme shared identical fragments with human autotaxin, a serum lysophospholipase D that produces LPA. Western blot analysis demonstrated that the 100-kDa protein was specifically recognized by an anti-human autotaxin antibody. Moreover, recombinant rat autotaxin was found to generate cPA in addition to LPA. No significant cPA- or LPA-producing activity was detected in autotaxin-depleted serum from bovine or human prepared by immunoprecipitation with an anti-autotaxin monoclonal antibody. These results indicate that the generation of cPA and LPA in serum is mainly attributed to autotaxin.


Human Molecular Genetics | 2014

Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies

Chie Shimamoto; Tetsuo Ohnishi; Motoko Maekawa; Akiko Watanabe; Hisako Ohba; Ryoichi Arai; Yoshimi Iwayama; Yasuko Hisano; Tomoko Toyota; Manabu Toyoshima; Katsuaki Suzuki; Yukihiko Shirayama; Kazuhiko Nakamura; Norio Mori; Yuji Owada; Tetsuyuki Kobayashi; Takeo Yoshikawa

Disturbances of lipid metabolism have been implicated in psychiatric illnesses. We previously reported an association between the gene for fatty acid binding protein 7 (FABP7) and schizophrenia. Furthermore, we identified and reported several rare non-synonymous polymorphisms of the brain-expressed genes FABP3, FABP5 and FABP7 from schizophrenia and autism spectrum disorder (ASD), diseases known to part share genetic architecture. Here, we conducted further studies to better understand the contribution these genes make to the pathogenesis of schizophrenia and ASD. In postmortem brains, we detected altered mRNA expression levels of FABP5 in schizophrenia, and of FABP7 in ASD and altered FABP5 in peripheral lymphocytes. Using a patient cohort, comprehensive mutation screening identified six missense and two frameshift variants from the three FABP genes. The two frameshift proteins, FABP3 E132fs and FABP7 N80fs, formed cellular aggregates and were unstable when expressed in cultured cells. The four missense mutants with predicted possible damaging outcomes showed no changes in intracellular localization. Examining ligand binding properties, FABP7 S86G and FABP7 V126L lost their preference for docosahexaenoic acid to linoleic acid. Finally, mice deficient in Fabp3, Fabp5 and Fabp7 were evaluated in a systematic behavioral test battery. The Fabp3 knockout (KO) mice showed decreased social memory and novelty seeking, and Fabp7 KO mice displayed hyperactive and anxiety-related phenotypes, while Fabp5 KO mice showed no apparent phenotypes. In conclusion, disturbances in brain-expressed FABPs could represent an underlying disease mechanism in a proportion of schizophrenia and ASD sufferers.


Biological Psychiatry | 2015

Utility of Scalp Hair Follicles as a Novel Source of Biomarker Genes for Psychiatric Illnesses

Motoko Maekawa; Kazuo Yamada; Manabu Toyoshima; Tetsuo Ohnishi; Yoshimi Iwayama; Chie Shimamoto; Tomoko Toyota; Yayoi Nozaki; Shabeesh Balan; Hideo Matsuzaki; Yasuhide Iwata; Katsuaki Suzuki; Mitsuhiro Miyashita; Mitsuru Kikuchi; Motoichiro Kato; Yohei Okada; Wado Akamatsu; Norio Mori; Yuji Owada; Masanari Itokawa; Hideyuki Okano; Takeo Yoshikawa

BACKGROUND Identifying beneficial surrogate genetic markers in psychiatric disorders is crucial but challenging. METHODS Given that scalp hair follicles are easily accessible and, like the brain, are derived from the ectoderm, expressions of messenger RNA (mRNA) and microRNA in the organ were examined between schizophrenia (n for first/second = 52/42) and control subjects (n = 62/55) in two sets of cohort. Genes of significance were also analyzed using postmortem brains (n for case/control = 35/35 in Brodmann area 46, 20/20 in cornu ammonis 1) and induced pluripotent stem cells (n = 4/4) and pluripotent stem cell-derived neurospheres (n = 12/12) to see their role in the central nervous system. Expression levels of mRNA for autism (n for case/control = 18/24) were also examined using scalp hair follicles. RESULTS Among mRNA examined, FABP4 was downregulated in schizophrenia subjects by two independent sample sets. Receiver operating characteristic curve analysis determined that the sensitivity and specificity were 71.8% and 66.7%, respectively. FABP4 was expressed from the stage of neurosphere. Additionally, microarray-based microRNA analysis showed a trend of increased expression of hsa-miR-4449 (p = .0634) in hair follicles from schizophrenia. hsa-miR-4449 expression was increased in Brodmann area 46 from schizophrenia (p = .0007). Finally, we tested the expression of nine putative autism candidate genes in hair follicles and found decreased CNTNAP2 expression in the autism cohort. CONCLUSIONS Scalp hair follicles could be a beneficial genetic biomarker resource for brain diseases, and further studies of FABP4 are merited in schizophrenia pathogenesis.


Glia | 2016

Astrocyte-Expressed FABP7 Regulates Dendritic Morphology and Excitatory Synaptic Function of Cortical Neurons

Majid Ebrahimi; Yui Yamamoto; Kazem Sharifi; Hiroyuki Kida; Yoshiteru Kagawa; Yuki Yasumoto; Ariful Islam; Hirofumi Miyazaki; Chie Shimamoto; Motoko Maekawa; Dai Mitsushima; Takeo Yoshikawa; Yuji Owada

Fatty acid binding protein 7 (FABP7) expressed by astrocytes in developing and mature brains is involved in uptake and transportation of fatty acids, signal transduction, and gene transcription. Fabp7 knockout (Fabp7 KO) mice show behavioral phenotypes reminiscent of human neuropsychiatric disorders such as schizophrenia. However, direct evidence showing how FABP7 deficiency in astrocytes leads to altered brain function is lacking. Here, we examined neuronal dendritic morphology and synaptic plasticity in medial prefrontal cortex (mPFC) of Fabp7 KO mice and in primary cortical neuronal cultures. Golgi staining of cortical pyramidal neurons in Fabp7 KO mice revealed aberrant dendritic morphology and decreased spine density compared with those in wild‐type (WT) mice. Aberrant dendritic morphology was also observed in primary cortical neurons co‐cultured with FABP7‐deficient astrocytes and neurons cultured in Fabp7 KO astrocyte‐conditioned medium. Excitatory synapse number was decreased in mPFC of Fabp7 KO mice and in neurons co‐cultured with Fabp7 KO astrocytes. Accordingly, whole‐cell voltage‐clamp recording in brain slices from pyramidal cells in the mPFC showed that both amplitude and frequency of action potential‐independent miniature excitatory postsynaptic currents (mEPSCs) were decreased in Fabp7 KO mice. Moreover, transplantation of WT astrocytes into the mPFC of Fabp7 KO mice partially attenuated behavioral impairments. Collectively, these results suggest that astrocytic FABP7 is important for dendritic arbor growth, neuronal excitatory synapse formation, and synaptic transmission, and provide new insights linking FABP7, lipid homeostasis, and neuropsychiatric disorders, leading to novel therapeutic interventions. GLIA 2016;64:48–62


Molecular Autism | 2014

Exon resequencing of H3K9 methyltransferase complex genes, EHMT1, EHTM2 and WIZ, in Japanese autism subjects.

Shabeesh Balan; Yoshimi Iwayama; Motoko Maekawa; Tomoko Toyota; Tetsuo Ohnishi; Manabu Toyoshima; Chie Shimamoto; Kayoko Esaki; Kazuo Yamada; Yasuhide Iwata; Katsuaki Suzuki; Masayuki Ide; Motonori Ota; Satoshi Fukuchi; Masatsugu Tsujii; Norio Mori; Yoichi Shinkai; Takeo Yoshikawa

BackgroundHistone H3 methylation at lysine 9 (H3K9) is a conserved epigenetic signal, mediating heterochromatin formation by trimethylation, and transcriptional silencing by dimethylation. Defective GLP (Ehmt1) and G9a (Ehmt2) histone lysine methyltransferases, involved in mono and dimethylation of H3K9, confer autistic phenotypes and behavioral abnormalities in animal models. Moreover, EHMT1 loss of function results in Kleefstra syndrome, characterized by severe intellectual disability, developmental delays and psychiatric disorders. We examined the possible role of histone methyltransferases in the etiology of autism spectrum disorders (ASD) and suggest that rare functional variants in these genes that regulate H3K9 methylation may be associated with ASD.MethodsSince G9a-GLP-Wiz forms a heteromeric methyltransferase complex, all the protein-coding regions and exon/intron boundaries of EHMT1, EHMT2 and WIZ were sequenced in Japanese ASD subjects. The detected variants were prioritized based on novelty and functionality. The expression levels of these genes were tested in blood cells and postmortem brain samples from ASD and control subjects. Expression of EHMT1 and EHMT2 isoforms were determined by digital PCR.ResultsWe identified six nonsynonymous variants: three in EHMT1, two in EHMT2 and one in WIZ. Two variants, the EHMT1 ankyrin repeat domain (Lys968Arg) and EHMT2 SET domain (Thr961Ile) variants were present exclusively in cases, but showed no statistically significant association with ASD. The EHMT2 transcript expression was significantly elevated in the peripheral blood cells of ASD when compared with control samples; but not for EHMT1 and WIZ. Gene expression levels of EHMT1, EHMT2 and WIZ in Brodmann area (BA) 9, BA21, BA40 and the dorsal raphe nucleus (DoRN) regions from postmortem brain samples showed no significant changes between ASD and control subjects. Nor did expression levels of EHMT1 and EHMT2 isoforms in the prefrontal cortex differ significantly between ASD and control groups.ConclusionsWe identified two novel rare missense variants in the EHMT1 and EHMT2 genes of ASD patients. We surmise that these variants alone may not be sufficient to exert a significant effect on ASD pathogenesis. The elevated expression of EHMT2 in the peripheral blood cells may support the notion of a restrictive chromatin state in ASD, similar to schizophrenia.


Schizophrenia Research | 2017

Comprehensive association analysis of 27 genes from the GABAergic system in Japanese individuals affected with schizophrenia

Shabeesh Balan; Kazuo Yamada; Yoshimi Iwayama; Takanori Hashimoto; Tomoko Toyota; Chie Shimamoto; Motoko Maekawa; Shu Takagai; Tomoyasu Wakuda; Yosuke Kameno; Daisuke Kurita; Kohei Yamada; Mitsuru Kikuchi; Tasuku Hashimoto; Nobuhisa Kanahara; Takeo Yoshikawa

Involvement of the gamma-aminobutyric acid (GABA)-ergic system in schizophrenia pathogenesis through disrupted neurodevelopment has been highlighted in numerous studies. However, the function of common genetic variants of this system in determining schizophrenia risk is unknown. We therefore tested the association of 375 tagged SNPs in genes derived from the GABAergic system, such as GABAA receptor subunit genes, and GABA related genes (glutamate decarboxylase genes, GABAergic-marker gene, genes involved in GABA receptor trafficking and scaffolding) in Japanese schizophrenia case-control samples (n=2926; 1415 cases and 1511 controls). We observed nominal association of SNPs in nine GABAA receptor subunit genes and the GPHN gene with schizophrenia, although none survived correction for study-wide multiple testing. Two SNPs located in the GABRA1 gene, rs4263535 (Pallele=0.002; uncorrected) and rs1157122 (Pallele=0.006; uncorrected) showed top hits, followed by rs723432 (Pallele=0.007; uncorrected) in the GPHN gene. All three were significantly associated with schizophrenia and survived gene-wide multiple testing. Haplotypes containing associated variants in GABRA1 but not GPHN were significantly associated with schizophrenia. To conclude, we provided substantiating genetic evidence for the involvement of the GABAergic system in schizophrenia susceptibility. These results warrant further investigations to replicate the association of GABRA1 and GPHN with schizophrenia and to discern the precise mechanisms of disease pathophysiology.


Gene | 2017

A spontaneous and novel Pax3 mutant mouse that models Waardenburg syndrome and neural tube defects

Tetsuo Ohnishi; Ikuo Miura; Hisako Ohba; Chie Shimamoto; Yoshimi Iwayama; Shigeharu Wakana; Takeo Yoshikawa

BACKGROUND Genes responsible for reduced pigmentation phenotypes in rodents are associated with human developmental defects, such as Waardenburg syndrome, where patients display congenital deafness along with various abnormalities mostly related to neural crest development deficiency. OBJECTIVE In this study, we identified a spontaneous mutant mouse line Rwa, which displays variable white spots on mouse bellies and white digits and tail, on a C57BL/6N genetic background. Curly tail and spina bifida were also observed, although at a lower penetrance. These phenotypes were dominantly inherited by offspring. We searched for the genetic mechanism of the observed phenotypes. METHODS We harnessed a rapid mouse gene mapping system newly developed in our laboratories to identify a responsible gene. RESULTS We detected a region within chromosome 1 as a probable locus for the causal mutation. Dense mapping using interval markers narrowed the locus down to a 670-kbp region, containing four genes including Pax3, a gene known to be implicated in the types I and III Waardenburg syndrome. Extensive mutation screening of Pax3 detected an 841-bp deletion, spanning the promoter region and intron 1 of the gene. The defective allele of Pax3, named Pax3Rwa, lacked the first coding exon and co-segregated perfectly with the phenotypes, confirming its causal nature. The genetic background of Rwa mice is almost identical to that of inbred C57BL/6N. CONCLUSION These results highlight Pax3Rwa mice as a beneficial tool for analyzing biological processes involving Pax3, in particular the development and migration of neural crest cells and melanocytes.


Bioscience, Biotechnology, and Biochemistry | 2018

Thiosulfate promotes hair growth in mouse model

Motoko Maekawa; Tetsuo Ohnishi; Shabeesh Balan; Yasuko Hisano; Yayoi Nozaki; Hisako Ohba; Manabu Toyoshima; Chie Shimamoto; Chinatsu Tabata; Yuina Wada; Takeo Yoshikawa

ABSTRACT The present study describes the hair growth-promoting effects of sodium thiosulfate (STS), a widely used compound, in mice. STS accelerated hair growth in the “telogen model”, suggesting that it stimulates telogen hair follicles to reenter the anagen phase of hair growth. In the same model, STS potentiated hair growth in an additive manner with minoxidil (MXD), a drug used for the treatment of androgenic alopecia. Furthermore, in the “anagen model”, STS promoted hair growth, probably by promoting hair follicle proliferation. Since STS elevated the skin surface temperature, its hair growth-promoting activity may be partly due to vasorelaxation, similar to MXD. In addition, STS is known to generate a gaseous mediator, H2S, which has vasorelaxation and anti-inflammatory/anti-oxidative stress activities. Therefore, STS and/or provisionally its metabolite, H2S, may aid the hair growth process. Collectively, these results suggest that salts of thiosulfate may represent a novel and beneficial remedy for hair loss. Graphical Abstract We found the hair growth-promoting effects of sodium thiosulfate (STS) in mice. STS may represent a beneficial remedy for hair loss.


Scientific Reports | 2015

Investigation of the fatty acid transporter-encoding genes SLC27A3 and SLC27A4 in autism

Motoko Maekawa; Yoshimi Iwayama; Tetsuo Ohnishi; Manabu Toyoshima; Chie Shimamoto; Yasuko Hisano; Tomoko Toyota; Shabeesh Balan; Hideo Matsuzaki; Yasuhide Iwata; Shu Takagai; Kohei Yamada; Motonori Ota; Satoshi Fukuchi; Yohei Okada; Wado Akamatsu; Masatsugu Tsujii; Nobuhiko Kojima; Yuji Owada; Hideyuki Okano; Norio Mori; Takeo Yoshikawa

The solute carrier 27A (SLC27A) gene family encodes fatty acid transport proteins (FATPs) and includes 6 members. During fetal and postnatal periods of development, the growing brain requires a reliable supply of fatty acids. Because autism spectrum disorders (ASD) are now recognized as disorders caused by impaired early brain development, it is possible that functional abnormalities of SLC27A genes may contribute to the pathogenesis of ASD. Here, we confirmed the expression of SLC27A3 and SLC27A4 in human neural stem cells derived from human induced pluripotent stem cells, which suggested their involvement in the developmental stage of the central nervous system. Additionally, we resequenced the SLC27A3 and SLC27A4 genes using 267 ASD patient and 1140 control samples and detected 47 (44 novel and 29 nonsynonymous) and 30 (17 novel and 14 nonsynonymous) variants for the SLC27A3 and SLC27A4, respectively, revealing that they are highly polymorphic with multiple rare variants. The SLC27A4 Ser209 allele was more frequently represented in ASD samples. Furthermore, we showed that a SLC27A4 Ser209 mutant resulted in significantly higher fluorescently-labeled fatty acid uptake into bEnd3 cells, a mouse brain capillary-derived endothelial cell line, compared with SLC27A4 Gly209, suggesting that the functional change may contribute to ASD pathophysiology.


Journal of Neural Transmission | 2015

Sequencing and expression analyses of the synaptic lipid raft adapter gene PAG1 in schizophrenia

Shabeesh Balan; Yoshimi Iwayama; Kazuo Yamada; Tomoko Toyota; Tetsuo Ohnishi; Manabu Toyoshima; Chie Shimamoto; Masayuki Ide; Yasuhide Iwata; Katsuaki Suzuki; Mitsuru Kikuchi; Tasuku Hashimoto; Nobuhisa Kanahara; Takeo Yoshikawa; Motoko Maekawa

Collaboration


Dive into the Chie Shimamoto's collaboration.

Top Co-Authors

Avatar

Takeo Yoshikawa

RIKEN Brain Science Institute

View shared research outputs
Top Co-Authors

Avatar

Motoko Maekawa

RIKEN Brain Science Institute

View shared research outputs
Top Co-Authors

Avatar

Tetsuo Ohnishi

RIKEN Brain Science Institute

View shared research outputs
Top Co-Authors

Avatar

Manabu Toyoshima

RIKEN Brain Science Institute

View shared research outputs
Top Co-Authors

Avatar

Yoshimi Iwayama

RIKEN Brain Science Institute

View shared research outputs
Top Co-Authors

Avatar

Tomoko Toyota

RIKEN Brain Science Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shabeesh Balan

RIKEN Brain Science Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge